Actually, in our article, we raised the issue that short-term use of SSRIs is associated with increased risk of upper gastrointestinal bleeding just like aspirin and NSAIDs. Our data also showed that SSRIs in combination with either aspirin or NSAIDs would further increase such bleeding risk. However, we made no attempts to infer that aspirin is safer than NSAIDs when in combination with SSRIs with regard to the risk of gastrointestinal bleeding. In addition, we cannot agree with the proposed mechanism in trying to explain the seemly lower bleeding risk of aspirin than that of NSAIDs. The 95% confidence risk intervals of gastrointestinal bleeding overlapped between aspirin and NSAID users, suggesting nonsignificant differences in risk between the two drugs when in combination with SSRIs. Furthermore, we don’t agree that prescription patterns in Taiwan are different from those of Western countries. In Taiwan or in Western countries, aspirin is mainly used in low doses for the purpose of long-term cardiac protection. This is also the reason why most researchers are more interested in the risk of gastrointestinal bleeding among low-dose, but not high-dose, aspirin users. Furthermore, the major clinical applications for aspirin and NSAIDs are different (i.e., cardiac protection versus pain control). Thus, in our opinion, it is not justifiable to compare the risk of gastrointestinal bleeding between the two drugs.